Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more) Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Xencor Inc XNCR

Healthcare Biotechnology
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases. More than 20 candidates engineered with its XmAb technology are in clinical development, and three XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of... see more

Recent & Breaking News (NDAQ:XNCR)

Xencor Enters Global Collaboration and License Agreement With Janssen to Advance Plamotamab and XmAb CD28 Bispecific Antibody Combinations for the Treatment of Patients With B-Cell Malignancies

Business Wire October 4, 2021

Xencor to Present Data from the Phase 1 Study of Vudalimab (XmAb®717) and Four Research Programs at the SITC Annual Meeting

Business Wire October 1, 2021

Xencor to Present at the 2021 Cantor Virtual Global Healthcare Conference

Business Wire September 20, 2021

Xencor Reports Second Quarter 2021 Financial Results

Business Wire August 4, 2021

Xencor to Present at Upcoming Investor Conferences

Business Wire August 2, 2021

Xencor to Host Second Quarter 2021 Financial Results Webcast and Conference Call on August 4, 2021

Business Wire July 28, 2021

Xencor to Present at the Jefferies Virtual Healthcare Conference

Business Wire May 27, 2021

Sotrovimab (VIR-7831), an Investigational Antibody Utilizing Xencor's Xtend(TM) Technology, Receives U.S. FDA Emergency Use Authorization for the Treatment of COVID-19

Business Wire May 26, 2021

Xencor and Bristol Myers Squibb Enter License Agreement for Use of Xtend(TM) XmAb® Technology in SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19

Business Wire May 25, 2021

Xencor to Present at the 2021 RBC Capital Markets Global Healthcare Virtual Conference

Business Wire May 12, 2021

Xencor Reports First Quarter 2021 Financial Results

Business Wire May 5, 2021

Xencor Doses First Subject in Phase 1 Study of XmAb®564, an Engineered IL-2 Cytokine in Development for Autoimmune Diseases

Business Wire April 28, 2021

Xencor to Host First Quarter 2021 Financial Results Webcast and Conference Call on May 5, 2021

Business Wire April 28, 2021

Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody and Cytokine Programs at the AACR Annual Meeting 2021

Business Wire April 10, 2021

Zenas BioPharma Launches as a Cross-Border Biopharmaceutical Company to Bring Innovation to the Development and Delivery of Immune-Based Therapies

GlobeNewswire March 23, 2021

Xencor to Present Preclinical Data from Four Preclinical XmAb® Bispecific Antibody and Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2021

Business Wire March 10, 2021

Xencor to Present at the Barclays Global Healthcare Conference

Business Wire March 3, 2021

Xencor and UCLA Enter Collaboration to Discover and Develop Novel XmAb® Therapeutics

Business Wire February 25, 2021

Xencor Reports Fourth Quarter and Full Year 2020 Financial Results

Business Wire February 23, 2021

Xencor to Host Fourth Quarter and Full Year 2020 Financial Results Webcast and Conference Call on February 23, 2021

Business Wire February 16, 2021